Buy AcuityAds for a double, Echelon says

AcuityAds (AcuityAds Stock Quote, Chart TSXV:AT) has sprinted out of the gate in 2019 following on two quarters of outperformance, but there’s more upside to come, says Rob Goff of Echelon Wealth Partners, who on Tuesday reiterated his “Speculative Buy” rating and price target of $3.60 per share, representing a projected return of 116 per cent at the time of publication.

Along with the robust financials over the past two quarters, AcuityAds announced in February that it had signed a global financial firm to a $4.5 million contract, which was subsequently increased to $7.5 million in March. Its largest customer to date, Goff says that the signing reaffirms his confidence in management’s ability to execute and secure more large contracts.

“We believe marquee wins validate AT’s AI technology/platform, open doors for further wins, build investor support and put AT under closer watch by competitors and potential acquirors. Consequently, we maintain our bullish organic view that sees further upside from takeover considerations not fully reflected in our price target,” says Goff.

Further, Goff sees a valuation gap between AT and larger competitor The Trade Desk, which is valued at 14.7x EV/Revenue and 50.0x EV/EBITDA for 2019 compared to AT’s 0.8x and 8.4x, respectively.

“The EV/EBITDA multiple for AT reflects its scaling with modest 2019 EBITDA margin of just 10.0 per cent versus The Trade Desk, where margins are forecasted at 29.5 per cent in 2019 and 24.9 per cent in 2018. While The Trade Desk’s scale, capital flexibility, and execution warrant a premium, the valuation gap warrants consideration,” says Goff.

The analyst sees AcuityAds generating fiscal 2019 revenue and Adjusted EBITDA of $97.0 million and $9.7 million, respectively, and fiscal 2020 revenue and Adjusted EBITDA of $116.0 million and $14.4 million, respectively.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: at
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago